Digital Health Technologies & Digital Biomarkers
Optimise protocol strategies with fit-for-purpose digital measures
ICON supports sponsors in accelerating and improving the assessment, selection and deployment of evidence-backed digital measures in clinical trials.
Our proprietary Atlas platform provides the most comprehensive insights on AI-powered biomarkers, multi-modal technologies, wearable sensors and other digital health technologies.
With 18,000+ digital measures gathered from 3,600 connected sensors spanning more than 1,300 medical conditions across 20 therapeutic areas and backed by more than 15,000 pieces of evidence, deploying the Atlas platform early in the trial lifecycle helps de-risk endpoint selection and optimize protocol design, and ensures the prioritisation of patient-centred outcomes.
The Atlas platform is based on comprehensive data:
-
18,000+
digital measures and biomarkers -
3,600+
digital health technologies
-
1,700
clinical trials -
15,000+
peer reviewed publications, research papers and conference abstracts
Atlas benefits:
- De-risk trial deployment with validated, scientifically-backed tools and assessments to capture robust data
- Optimise protocol strategies throughout the trial lifecycle, increasing likelihood of regulatory approval
- Development of patient-centered clinical strategies, reducing participation burden and measuring what matters to patients
- 4x faster decision making with Atlas compared to using traditional research methods
Media contributions
Blog contributions
-
Enabling a new way to select fit-for-purpose COAs to simplify clinical protocols
For clinical researchers, getting to a finished protocol is a delicate art in navigating research, regulatory precedence, and institutional knowledge. And complexity continues to grow - more regulations, more endpoints per trial, more amendments, and more options (in-person or remote assessments).
-
Outcome measures: Driving precision health strategies forward
ICON has been speaking, collaborating, and building with top pharma throughout the year to help them develop better drugs, faster, for patients. Here are a few observations from this year.
-
Digital endpoints widely adopted in pharmaceutical and biotech-sponsored clinical trials
Over 130 pharma and biotech organizations have relied on AI-powered digital biomarkers and sensor-derived clinical outcome assessments (COAs) to capture patient-centered endpoints.
-
The rise of precision outcome measures
Precision outcome measures are the means by which to evaluate a meaningful change on the exact outcome of interest, regardless of tool or instrument.
-
Outcome Measures: Driving forward patient-centered clinical trials
ICON’s Outcome Measures service aims to drive forward patient-centered treatments while also helping sponsors increase the likelihood of regulatory approval.
.jpg?crop=yes&w=555&h=339&a=0,0&itok=-7j9N19K "Insights-page-(1)"){kind=icon}
mHealth & Wearables insights
Our mHealth & Wearables insights will help you to understand and successfully address the complexities of implementation of wearable devices in trial design, execution and reporting.
Learn more
Request an Atlas platform demo or arrange a meeting